- Recruiting
NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Updated: Oct 20, 2022
NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Evaluation of myeloma disease burden is currently suboptimal. This limits treatment planning and evaluation of residual disease following treatment. 89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.
Sponsor
Hoag Memorial Hospital Presbyterian
ClinicalTrials.gov Identifier: NCT04405167
ClinicalTrials.gov Identifier: NCT04814615
Official Title: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications
First Posted : March 24, 2021
Click here to see details on ClinicalTrials.gov
Drug: 89Zr-daratumumab PET/CT
Radiology. June 2020
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Location
- Florida: Sylvester Comprehensive Cancer Center - University of Miami
- United States, California